Sounds of Science Podcast

Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

Previous articleINFOGRAPHIC: Spotlight on How a Discovery Program Was Born
Next articleTargeting CD44s Molecule May Open New Door to Improved Cancer Therapies